Pharmaceutical

HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology

GlobalData has analysed HTA decisions made for branded medicines in 5EU from 2018 to 2022, with a focus on oncology.

Jul 13, 2023 - 20:00
HTA outcomes in the 5EU are growing at 27% with a deep commitment to oncology
GlobalData has analysed HTA decisions made for branded medicines in 5EU from 2018 to 2022, with a focus on oncology.
Read the original article

Tags:

Previous Article

Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032

Next Article

Roche eyes alternate mode of administration for Ocrevus in MS

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How did hiring in the US pharma industry perform in Q3 ...

Oct 19, 2023

STAT+: FDA warns medical device makers about rise in fabricated data

STAT+: FDA warns medical device makers about rise in fa...

Feb 21, 2024

STAT+: House committees strike deal on health transparency, PBM reform package

STAT+: House committees strike deal on health transpare...

Sep 6, 2023